At the news
? NEUTRALIMPACT 3/10 6-K filed May 12, 2026 at 09:30 ET
Evaxion announced it will present preclinical data for EVX-04, an off-the-shelf therapeutic AML vaccine, at the EHA 2026 Congress in June. The data is preclinical and the company plans to submit a clinical trial application in H2 2026. This is a routine pipeline update with no financial data or near-term catalyst.
- Evaxion to present functional characterization data for EVX-04 at EHA 2026 Congress on June 13, 2026
- EVX-04 is an off-the-shelf therapeutic vaccine targeting acute myeloid leukemia (AML)
- Preclinical data shows EVX-04 prevents tumor growth in preclinical models
- Company plans to submit a clinical trial application in the second half of 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access